Bentley Systems Announces Seequent’s Acquisition of Minalytix
14.9.2021 23:01:00 EEST | Business Wire | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that its Seequent business unit has acquired Canadian software company Minalytix, the developer of MX Deposit. The acquisition extends Seequent’s cloud capabilities and solutions for mining, including greenfield exploration, resource development, and mining production. Prior to the transaction, Seequent held a minority shareholding in Minalytix, and its partnership included exclusive global rights to sell MX Deposit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914006105/en/
Seequent already integrates its Leapfrog, Oasis montaj, Target, and Imago solutions with MX Deposit, streamlining processes and increasing efficiency for geologists, engineers, and other stakeholders. For example, users can easily pull data captured in MX Deposit into Target to generate sections or Leapfrog Geo for 3D modeling and analysis of drill hole data. Teams can collaborate on models with Seequent Central and share with stakeholders using Leapfrog Viewer. (Photo: Business Wire)
MX Deposit simplifies and controls how drill hole and other field data is collected, managed, and shared throughout the lifecycle of a deposit. Mining exploration teams can configure the solution for various activities, including diamond and percussive drilling, grade control, underground face sampling, metallurgical sampling, stockpile sampling, and sampling mill circuits. MX Deposit closes gaps in a project’s data collection, streamlines workflow, reduces errors, and provides an audit trail to improve data confidence and act as a single source of truth for project data. MX Deposit is easy to use and configure and works anywhere online and offline, delivering valuable insights across all mining projects. Real-time collaboration is enabled with live project data.
Mining companies use MX Deposit, in conjunction with other geophysics and geology data management and modeling tools, to find, develop, and manage world-class deposits, and to enable teams to manage risk and make better, more profitable decisions. Data can be easily integrated into MX Deposit in order to provide context that delivers more knowledge and better decision making. Seequent already integrates its Leapfrog, Oasis montaj, Target, and Imago solutions with MX Deposit, streamlining processes and increasing efficiency for geologists, engineers, and other stakeholders. MX Deposit unlocks value from drilling, one of the largest investments for any mining and exploration company, with enduring high-quality data.
MX Deposit is an affordable Software-as-a-Service (SaaS) solution and auto-scales to meet users’ needs, from small to multi-national companies. Users can create a customized data management solution within hours, not days, to collect and control drill hole and other field data and immediately gain insights across all projects. There are no limits on data users can store, with some logging millions of samples and blast holes and tens of thousands of drill holes.
Graham Grant, chief executive officer of Seequent, said, “We’re excited to welcome the Minalytix team to Seequent, following our successful collaboration, to broaden the mining workflow through further cloud capabilities. Drill and sample data are the lifeblood for mining companies when exploring, and MX Deposit naturally aligns with our mining and exploration portfolio, including newly acquired geoscientific imagery platform Imago. We have already done a great job of integrating the software and now we are excited to integrate the team.”
Minalytix Co-founder and CEO David Peres said, “We’re delighted to join Seequent as it allows us to deliver on our founding mission to impact the mining industry positively. We partnered exclusively with Seequent a couple of years ago as they had earned a reputation as a trusted mining innovator with a global reach. As a result, demand for MX Deposit increased in leaps and bounds. With Seequent’s expertise and support, MX Deposit will be able to reach its full potential.”
For more information, please visit https://www.mxdeposit.net/
Caption: Seequent already integrates its Leapfrog, Oasis montaj, Target, and Imago solutions with MX Deposit, streamlining processes and increasing efficiency for geologists, engineers, and other stakeholders. For example, users can easily pull data captured in MX Deposit into Target to generate sections or Leapfrog Geo for 3D modeling and analysis of drill hole data. Teams can collaborate on models with Seequent Central and share with stakeholders using Leapfrog Viewer.
Caption: MX Deposit harnesses the collective power of a team to unlock value from drilling and sampling data. Users can build in important data validation rules into the system and collect quality data that will stand the test of time. A real-time activity feed allows team members to post comments and questions globally or to a specific group of people. In addition, users can tag images and comments to particular drill holes, samples, tables, records or values within a record. As a result, a complete audit trail is captured on every piece of data.
Caption: MX Deposit closes gaps in a project’s data collection from sample collection to lab analysis, ensuring company-wide consistency. Users can import assay results from a laptop in the office and even when off the grid in remote areas can grab samples with native Android and iOS applications that enable work fully offline. Data is automatically synced to the web application once users are back online.
##
About Seequent
Seequent, a Bentley company, is a world leader in the development of powerful geoscience analysis, modeling, and collaborative technologies for understanding geoscience and engineering design solutions. Our solutions enable people to analyze complex data, manage risk, and ultimately make better decisions about earth, environment, and energy challenges.
Seequent software is used on large-scale projects globally, including road and rail tunnel construction, groundwater detection and management, geothermal exploration, subsea infrastructure mapping, resource evaluation, and subterranean storage of spent nuclear fuel.
Seequent’s global footprint includes its Christchurch-based HQ and R&D centers in Christchurch and Canada with a network of offices across Asia/Pacific, Africa, South America, North America, and Europe, servicing organizations with leading subsurface solutions in over 100 countries. For more information, please visit www.seequent.com or follow Seequent on LinkedIn or Twitter.
About Bentley Systems
Bentley Systems (Nasdaq: BSY) is the infrastructure engineering software company. We provide innovative software to advance the world’s infrastructure – sustaining both the global economy and environment. Our industry-leading software solutions are used by professionals, and organizations of every size, for the design, construction, and operations of roads and bridges, rail and transit, water and wastewater, public works and utilities, buildings and campuses, mining, and industrial facilities. Our offerings include MicroStation-based applications for modeling and simulation, ProjectWise for project delivery, AssetWise for asset and network performance, Seequent’s leading geosciences software portfolio, and the iTwin platform for infrastructure digital twins. Bentley Systems employs more than 4,000 colleagues and generates annual revenues of more than $800 million in 172 countries.
www.bentley.com
© 2021 Bentley Systems, Incorporated. Bentley, the Bentley logo, AssetWise, Imago, iTwin, Leapfrog, Leapfrog Geo, MicroStation, Minalytix, MX Deposit, Oasis montaj, ProjectWise, Seequent, the Seequent logo, and Target are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914006105/en/
Contact information
Christine Byrne
+1 203 805 0432
Christine.Byrne@bentley.com
Follow us on Twitter:
@BentleySystems
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom